The US Food and Drug Administration (FDA) has begun piloting a new “one-day inspectional assessment” model designed to broaden oversight across regulated industries while making inspections more targeted and efficient.
The new model uses shorter, focused visits intended to complement, rather than replace, traditional multi-day inspections.
The agency says the approach will allow inspectors to cover more facilities while strengthening the risk intelligence used to prioritise future inspections.
The pilot is being rolled out across a range of programmes, including biologics, medical products, human and animal foods, and clinical research sites.
Facilities are selected using risk-based criteria such as product type, compliance history and operational characteristics, with early use of advanced analytics and AI-supported targeting flagged in initial documentation.
According to the FDA, the one-day assessments are mainly directed at lower-risk facilities, where shorter visits can confirm compliance while reducing operational disruption.
Inspectors can extend an assessment beyond a single day if significant observations are identified.
As of late April 2026, around 46 assessments had been completed under the pilot, with most resulting in “No Action Indicated” outcomes.
Findings from the programme, including recurring compliance themes and facility-level risk signals, are being fed into updated risk models to refine future inspection targeting.
The FDA says the initiative is intended to expand surveillance coverage without reducing scrutiny, while also improving its ability to detect gaps between registered and actual operations across facilities.
The pilot will continue through fiscal year 2026, with performance tracked through measures including inspection duration, escalation rates and the usefulness of findings in enforcement planning.
Implications for cleanroom manufacturers of the new FDA inspection pilot
For cleanroom and advanced manufacturing facilities, including pharmaceutical, biologics and advanced therapy sites, the pilot introduces a greater emphasis on reviewing contamination control measures, batch and validation records, and environmental monitoring data through shorter assessment visits.
The FDA has said facilities are being selected using risk-based criteria, with factors such as compliance history and operational characteristics influencing oversight. Under the pilot, lower-risk sites may be subject to shorter assessments, while inspections can be expanded where observations warrant further review.